Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2018-08-24

Clinical Trial Update: A Study of Lebrikizumab in Participants With Idiopathic Pulmonary Fibrosis (IPF) [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for lebekizumab in idiopathic pulmonary fibrosis has completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Lebrikizumab (lebrikizumab)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Idiopathic Pulmonary Fibrosis | Phase 2 | Status: COMPLETED | Results posted: 2018-08-24